Cystic Fibrosis
Conditions
Brief summary
identify and validate biomarkers that might reflect partial restoration of CFTR function and can be used to monitor disease progression, and ii) evaluate the mechanistic effects of CFTR modulators and other relevant therapies in individuals with CF
Detailed description
Cystic fibrosis (CF) is a genetic disorder caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Over 1,900 mutations, categorized into five genotypic or functional classes are implicated in causing CF. Severity of disease varies widely in CF based on CFTR-dependent and independent factors. Progressive obstructive lung disease is the main determinant of morbidity and mortality in CF; therefore it is critical to identify biomarker profiles that reflect and predict this phenotypic variability, and understand their relationship to residual CFTR activity. Emerging CFTR modulator therapies that directly target defective CFTR are being evaluated in pivotal clinical trials and may become available in the next few years. It is not known how partial restoration of CFTR function might impact CF disease progression and disease-related biomarkers. Thus there is urgent need to i) identify and validate biomarkers that might reflect partial restoration of CFTR function and can be used to monitor disease progression, and ii) evaluate the mechanistic effects of CFTR modulators and other relevant therapies in individuals with CF
Interventions
OTHERObservational
Sponsors
Cystic Fibrosis Foundation
University of Alabama at Birmingham
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Part A COHORT 1: * 1\. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative. 2\. Be willing and able to adhere to the study visit schedule and other protocol requirements 3. Male or female ≥ 12 years of age at Visit 1. 4. Have a body mass index (BMI) of: * For subjects ≥ 18 years of age: ≤ 30 kg/m2 * For subjects 12 - 17 years of age: ≤ 95th percentile 5. Be a non-smoker for ≥ 1 year at screening and have ≤ 10 pack-year history of smoking. 6\. To participate in the optional DNA banking component of this study, subject must have signed the informed consent indicating willingness to participate in the genomic component of the study. Refusal to give consent for this component does not exclude a subject from participation in the study. Inclusion Cohorts 2-3 1. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative. 2. Male or female ≥ 12 years of age at Visit 1. 3. Documentation of a CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and the following criteria: Cohort 2: (Partial Function CFTR CF) * Two mutations in the CFTR gene: * At least one allele must be a Class IV or V mutation * The second allele can be within any CFTR mutation class. * Pancreatic sufficient (based on the absence of daily PERT use) * At least one historic sweat chloride ≥60 mEq/L by quantitative pilocarpine iontophoresis test (QPIT) OR sweat chloride results ≥ 40, but \< 60mEQ/L upon permission of the PROSPECT Investigator-Sponsors. Cohort 3: (Absent Function CF) • Two class I or II CFTR mutations 4. Enrolled in the Cystic Fibrosis Foundation Patient Registry. Patients may enroll in the Registry at Visit 1 if not previously enrolled. 5. Clinically stable with no significant changes in health status within 2 weeks prior to Visit 1. 6. Be a non-smoker for ≥ 1 year at screening and have ≤ 10 pack-year history of smoking. 7. To participate in the optional DNA banking component of this study, subject must have signed the informed consent indicating willingness to participate in the genomic component of the study. Refusal to give consent for this component does not exclude a subject from participation in the study Part B Inclusion 1. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative. 2. Physician decision to treat with ivacaftor/lumacaftor. 3. Completion of at least Visit 1 and Visit 2 of Part A
Exclusion criteria
PART A COHORT 1 1. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data. 2. A history of any clinically significant medical illness or medical disorder that requires ongoing systemic medical therapy, including (but not limited to) cardiovascular disease, neuromuscular disease, hematological disease including bleeding disorders, chronic respiratory disease (including persistent asthma), hepatic or gastrointestinal (GI) disease, neurological disease, neoplastic disease, renal diseases, or endocrine disorders including diabetes. 3. Acute illness requiring any new prescription or over-the-counter treatment within 14 days prior to Visit 1. 4. Major or traumatic surgery within 12 weeks prior to Visit 1. 5. For females of child-bearing potential: a positive pregnancy test at Visit 1. 6. Initiation of any new chronic therapy within 28 days prior to Visit 1. 7. Use of an investigational agent within 28 days prior to Visit 1. Exclusion Part A COHORTS 2-3 1. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data. 2. Initiation of newly prescribed antibiotics \[oral, intravenous (IV), and/or inhaled\] for acute respiratory symptoms within 2 weeks of Visit 1. 3. Major or traumatic surgery within 12 weeks prior to Visit 1. 4. For females of child-bearing potential: a positive pregnancy test at Visit 1. 5. Initiation of any new chronic therapy (e.g., ibuprofen Pulmozyme®, hypertonic saline, azithromycin, TOBI®, Cayston®) within 4 weeks prior to Visit 1. 6. Use of an investigational agent within 28 days prior to Visit 1. 7. Use of oral corticosteroids in doses exceeding 10 mg prednisone/day or 20 mg prednisone/every other day (subjects on oral steroids will be on stable doses for \> 12 weeks prior to visit 1). 8. Active treatment for nontuberculous mycobacterial (NTM) infection, consisting of ≥ two antibiotics (oral, IV, and/or inhaled). 9. Use of CFTR modulator therapy such as ivacaftor (Kalydeco®) within 28 days prior to Visit 1. 10. History of lung or liver transplantation, or listing for organ transplantation. Exclusion PART B 1. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data. 2. Initiation of newly prescribed antibiotics \[oral, intravenous (IV), and/or inhaled\] for acute respiratory symptoms within 2 weeks of Visit 4. 3. Initiation of any new chronic therapy (e.g., ibuprofen, Pulmozyme®, hypertonic saline, azithromycin, TOBI®, Cayston®) within 4 weeks prior to Visit 4. 4. Use of an investigational agent within 28 days prior to Visit 4. 5. Use of oral corticosteroids in doses exceeding 10 mg prednisone/day or 20 mg prednisone/every other day (subjects on oral steroids will be on stable doses for \> 12 weeks prior to Visit 4). 6. Active treatment for nontuberculous mycobacterial (NTM) infection, consisting of ≥ two antibiotics (oral, IV, and/or inhaled). 7. Use of CFTR modulator therapy such as ivacaftor (Kalydeco®) within 28 days prior to Visit 4.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sweat Chloride by Cohort (Part A Only) | For cohort 1, sweat chloride at Day 0 is time frame. For cohorts 2-3, sweat chloride averaged across all 3 visits at days 0, 14 and 90 is time frame. | This is the primary endpoint for Part A per the PROSPECT protocol. Mean sweat chloride was not reported for Part B, as it is not a relevant statistic. For cohort 1, sweat chloride is from day 0 only. For cohorts 2-3, sweat chloride was averaged from days 0, 14, 90 via a random intercept longitudinal model. |
| 6 Month Change in FEV1 Percent Predicted (Part B Only) | Baseline and 6 months | This is the primary endpoint for Part B per the PROSPECT protocol. Change in FEV1 Percent Predicted is only relevant for Part B as it captures changes in lung function post-initiation of Ivacaftor/Lumacaftor. |
Countries
United States
Participant flow
Recruitment details
Enrollment Period: March 2015 - June 2017 (revised)
Participants by arm
| Arm | Count |
|---|---|
| Part A (Cohort 1) • Cohort 1: Healthy Controls
Observational | 55 |
| Part A (Cohort 2) • Cohort 2: Partial CFTR function (CF class IV/V)
Observational | 40 |
| Part A (Cohort 3) • Cohort 3: Absent CFTR function (CF Class I/II) | 164 |
| Part B F508del homozygous CF patients who initiated Lumacaftor/Ivacaftor
Observational (pre/post study) | 193 |
| Total | 452 |
Baseline characteristics
| Characteristic | Total | Part A (Cohort 1) | Part A (Cohort 2) | Part A (Cohort 3) | Part B |
|---|---|---|---|---|---|
| Age, Continuous | 22.0 years STANDARD_DEVIATION 11.7 | 25.6 years STANDARD_DEVIATION 10.1 | 32.3 years STANDARD_DEVIATION 18.1 | 21.8 years STANDARD_DEVIATION 9.6 | 19.0 years STANDARD_DEVIATION 10.6 |
| Age, Customized Age Category >= 12 - 17 | 173 Participants | 13 Participants | 11 Participants | 77 Participants | 72 Participants |
| Age, Customized Age Category >= 18 - 29 | 138 Participants | 30 Participants | 13 Participants | 53 Participants | 42 Participants |
| Age, Customized Age Category >= 30 | 96 Participants | 12 Participants | 16 Participants | 34 Participants | 34 Participants |
| Age, Customized Age Category >=6 - 11 Y | 45 Participants | 0 Participants | 0 Participants | 0 Participants | 45 Participants |
| FEV1 % Predicted | 83.9 % Predicted STANDARD_DEVIATION 23.1 | — | 86.9 % Predicted STANDARD_DEVIATION 24.6 | 81.8 % Predicted STANDARD_DEVIATION 23.4 | 85.0 % Predicted STANDARD_DEVIATION 22.4 |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 7 Participants | 6 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 7 Participants | 2 Participants | 2 Participants | 3 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 11 Participants | 3 Participants | 0 Participants | 6 Participants | 2 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants | 2 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 424 Participants | 42 Participants | 38 Participants | 155 Participants | 189 Participants |
| Sex: Female, Male Female | 240 Participants | 26 Participants | 24 Participants | 84 Participants | 106 Participants |
| Sex: Female, Male Male | 212 Participants | 29 Participants | 16 Participants | 80 Participants | 87 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 0 |
| other Total, other adverse events | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 |
Outcome results
Primary
6 Month Change in FEV1 Percent Predicted (Part B Only)
This is the primary endpoint for Part B per the PROSPECT protocol. Change in FEV1 Percent Predicted is only relevant for Part B as it captures changes in lung function post-initiation of Ivacaftor/Lumacaftor.
Time frame: Baseline and 6 months
Population: Change in FEV1 % predicted was measured in all participants who had baseline visit and 6 month visit.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Part A (Cohort 1) | 6 Month Change in FEV1 Percent Predicted (Part B Only) | -0.2 Percent Predicted |
Primary
Sweat Chloride by Cohort (Part A Only)
This is the primary endpoint for Part A per the PROSPECT protocol. Mean sweat chloride was not reported for Part B, as it is not a relevant statistic. For cohort 1, sweat chloride is from day 0 only. For cohorts 2-3, sweat chloride was averaged from days 0, 14, 90 via a random intercept longitudinal model.
Time frame: For cohort 1, sweat chloride at Day 0 is time frame. For cohorts 2-3, sweat chloride averaged across all 3 visits at days 0, 14 and 90 is time frame.
Population: Participants with Sweat Chloride measure. For Cohort 1, sweat chloride was collected at Visit 1 only (Day 0). Cohort 2 and 3 were collected at Days 0, 14 and 90.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Part A (Cohort 1) | Sweat Chloride by Cohort (Part A Only) | 22.0 mmol/L |
| Part A (Cohort 2) | Sweat Chloride by Cohort (Part A Only) | 81.0 mmol/L |
| Part A (Cohort 3) | Sweat Chloride by Cohort (Part A Only) | 101.4 mmol/L |